389 A phase 1, dose-escalation, first-in-human study of ARQ 087, an oral pan-FGFR inhibitor, in adult subjects with advanced solid tumors
Papadopoulos K, Tolcher A, Kittaneh M, Patniak A, Rasco D, Chambers G, Newth G, Savage R, Hall T, Schwartz B, Kazakin J, LoRusso P. 389 A phase 1, dose-escalation, first-in-human study of ARQ 087, an oral pan-FGFR inhibitor, in adult subjects with advanced solid tumors. European Journal Of Cancer 2014, 50: 125. DOI: 10.1016/s0959-8049(14)70515-5.Peer-Reviewed Original Research